# Monopar Therapeutics: overview MNPR · Nasdaq · CIK 1645469 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/mnpr.md) · [Financials](/companies/mnpr/financials.md) · [Filings](/companies/mnpr/filings.md) · [Insiders](/companies/mnpr/insiders.md) Latest reported revenue: [$0](/filings/0001437749-26-027164.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 12, 2026 (XBRL us-gaap:Revenues, accession 0001437749-26-027164). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001437749-26-016982.md) | [0.0 d](/filings/0001437749-26-027164.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 6-month figure less the 3-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 6-month figure less the 3-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Diluted EPS. XBRL not reported. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | [0.0](/filings/0001437749-25-009979.md) | [0.0](/filings/0001437749-26-010025.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.73)](/filings/0001654954-22-003701.md) | not reported | not reported | not reported | not reported | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/mnpr/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $121.7m | 1,312,129 | | Not compared | | [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $72.1m | 1,317,410 | | Not compared | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $61.8m | 667,207 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $32.3m | 348,819 | | Added +32,252 | | [DEERFIELD MANAGEMENT COMPANY, L.P.](/funds/1009258.md) | 2026-06-30 | $30.0m | 323,745 | | Unchanged | | [Saturn V Capital Management LP](/funds/1964437.md) | 2026-06-30 | $28.9m | 311,976 | | Reduced −33,650 | | [Siren, L.L.C.](/funds/2005245.md) | 2026-06-30 | $25.0m | 270,118 | | Unchanged | | [ADAR1 Capital Management, LLC](/funds/1940272.md) | 2026-06-30 | $20.1m | 217,595 | | Reduced −46,683 | | [Polar Capital Holdings Plc](/funds/1837309.md) | 2026-06-30 | $19.9m | 214,469 | | Reduced −12,057 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $19.4m | 209,711 | | Reduced −8,752 | ## Recent filings [All 531 filings](/companies/mnpr/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-12 | 13:30 ET | [8-K](/filings/0001437749-26-027165.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-027165 | | 2026-08-12 | 13:30 ET | [10-Q](/filings/0001437749-26-027164.md) | Quarterly report, period 2026-06-30 | 0001437749-26-027164 | | 2026-07-22 | 12:00 ET | [8-K](/filings/0001437749-26-024041.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-024041 | | 2026-06-30 | 12:00 ET | [8-K](/filings/0001437749-26-022086.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-022086 | | 2026-06-26 | 20:06 ET | [8-K](/filings/0001437749-26-021832.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-021832 | | 2026-06-23 | 12:00 ET | [8-K](/filings/0001437749-26-021350.md) | 5.07 Shareholder vote results | 0001437749-26-021350 | | 2026-05-29 | 20:56 ET | [8-K](/filings/0001437749-26-018896.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-018896 | | 2026-05-19 | 21:26 ET | [8-K](/filings/0001437749-26-017821.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-017821 | | 2026-05-14 | 18:00 ET | [10-Q](/filings/0001437749-26-016982.md) | Quarterly report, period 2026-03-31 | 0001437749-26-016982 | | 2026-05-14 | 18:00 ET | [8-K](/filings/0001437749-26-016981.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-016981 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-010025.md), filed Mar 27, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/627c0765-180d-4120-9782-359cb10d6f44) ## About the filer - CIK: 1645469 - Tickers: MNPR - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.